Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIPONASDAQ:MTVANASDAQ:NLSPNASDAQ:ONCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIPOLipella Pharmaceuticals$2.18-2.2%$2.43$1.97▼$12.00$5.56M0.26723,226 shs62,535 shsMTVAMetaVia$0.68+1.3%$1.15$0.65▼$5.30$5.92M0.21359,329 shs77,770 shsNLSPNLS Pharmaceutics$1.62+0.4%$1.51$1.30▼$18.39$5.82M-0.21850,126 shs10,135 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$9.88$1.56M1.1869,603 shsN/AA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIPOLipella Pharmaceuticals0.00%-9.17%-9.17%-43.81%-64.29%MTVAMetaVia0.00%-3.61%-7.37%-59.11%+68,449,900.00%NLSPNLS Pharmaceutics0.00%-1.45%+10.70%-28.49%+1,006.99%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-94.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLIPOLipella Pharmaceuticals0.7989 of 5 stars0.02.00.00.01.53.30.6MTVAMetaVia2.2533 of 5 stars3.50.00.00.03.10.01.3NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal Therapeutics1.2893 of 5 stars3.10.00.00.00.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIPOLipella Pharmaceuticals 0.00N/AN/AN/AMTVAMetaVia 3.00Buy$12.001,653.10% UpsideNLSPNLS Pharmaceutics 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideCurrent Analyst Ratings BreakdownLatest ONCT, LIPO, MTVA, and NLSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/21/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIPOLipella Pharmaceuticals$536.36K10.36N/AN/A$4.33 per share0.50MTVAMetaViaN/AN/AN/AN/A$3.44 per shareN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIPOLipella Pharmaceuticals-$4.62M-$4.08N/A∞N/A-882.82%-192.33%-154.24%N/AMTVAMetaVia-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%N/ANLSPNLS Pharmaceutics-$12.17MN/A0.00∞N/AN/AN/AN/A5/21/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/ALatest ONCT, LIPO, MTVA, and NLSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/A3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIPOLipella PharmaceuticalsN/A2.972.97MTVAMetaViaN/A2.412.41NLSPNLS PharmaceuticsN/A0.15N/AONCTOncternal TherapeuticsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIPOLipella Pharmaceuticals74.31%MTVAMetaVia1.37%NLSPNLS PharmaceuticsN/AONCTOncternal Therapeutics16.05%Insider OwnershipCompanyInsider OwnershipLIPOLipella Pharmaceuticals32.11%MTVAMetaVia1.05%NLSPNLS Pharmaceutics16.40%ONCTOncternal Therapeutics11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIPOLipella Pharmaceuticals42.55 million821,000Not OptionableMTVAMetaVia88.66 million8.53 millionN/ANLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataONCT, LIPO, MTVA, and NLSP HeadlinesRecent News About These CompaniesOncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.comMay 16 at 1:23 AM | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.comMay 8, 2025 | americanbankingnews.comOncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SECMarch 7, 2025 | globenewswire.comOncternal Therapeutics (NASDAQ:ONCT) Stock, Short Interest ReportNovember 26, 2024 | benzinga.comOncternal Therapeutics Reports Q3 2024 EarningsNovember 21, 2024 | markets.businessinsider.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal Therapeutics to Cut Most of Its WorkforceNovember 14, 2024 | marketwatch.comOncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and ImplicationsNovember 9, 2024 | markets.businessinsider.comONCT-534 Produces Tolerable Safety Outcomes in Relapsed/Refractory mCRPCOctober 23, 2024 | curetoday.comWhat’s Causing Oncternal Therapeutics Inc (ONCT) Stock’s -76.41% Drop Over the Last Six Months?October 23, 2024 | bovnews.comOncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534October 23, 2024 | markets.businessinsider.comMetastatic Prostate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024October 7, 2024 | theglobeandmail.comNorthland Securities Sticks to Its Buy Rating for Heron Therapeutics (HRTX)September 27, 2024 | markets.businessinsider.comEarlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?September 19, 2024 | medpagetoday.comStockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt InvestorsSeptember 16, 2024 | genengnews.comOncternal stops cancer trials and begins search for future business optionsSeptember 15, 2024 | endpts.comNorthland Capital Markets Downgrades Oncternal Therapeutics (ONCT)September 14, 2024 | msn.comOncternal stock crashes by 60% as it lays off staff and scraps trialsSeptember 14, 2024 | finance.yahoo.comOncternal to Lay Off 37% of Employees, Including CMOSeptember 13, 2024 | biospace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCT, LIPO, MTVA, and NLSP Company DescriptionsLipella Pharmaceuticals NASDAQ:LIPO$2.18 -0.05 (-2.24%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.10 -0.08 (-3.67%) As of 05/16/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.MetaVia NASDAQ:MTVA$0.68 +0.01 (+1.29%) As of 05/16/2025 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.NLS Pharmaceutics NASDAQ:NLSP$1.62 +0.01 (+0.39%) Closing price 05/16/2025 03:56 PM EasternExtended Trading$1.64 +0.03 (+1.78%) As of 05/16/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
